Strados Labs

Executive Summary

Strados Labs is a digital health company developing the RESP® Platform, a wearable stethoscope and respiratory monitoring system that captures and analyzes lung sounds such as cough, wheeze, and crackles. The platform is designed to enable objective measurement of respiratory health across care settings, from hospital to home, with applications in clinical research and disease management. By providing continuous, remote monitoring of respiratory symptoms, Strados aims to improve outcomes for patients with chronic respiratory conditions like asthma, COPD, and post-COVID complications, while also reducing healthcare costs through early detection and intervention. The respiratory monitoring market is growing rapidly, driven by the increasing prevalence of respiratory diseases and the shift toward home-based care. Strados Labs is positioned to capture value by offering a novel, non-invasive solution that addresses the limitations of current subjective assessment methods. With its focus on objective lung sound analysis, the platform has potential to become a standard tool in clinical trials and telemedicine. However, as a private, relatively early-stage company, Strados faces challenges in securing regulatory clearance and commercial traction. The next 12-18 months will be critical for demonstrating clinical utility and achieving key milestones.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for RESP Platform40% success
• Q3 2026Series A funding round completion60% success
• Q2 2026Partnership announcement with a top-10 pharmaceutical company for respiratory clinical trials35% success